Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="de Haard, Hans" or (type exact bookEditor and editor="de Haard, Hans")

Mark
Therapeutic bispecific antibody formats : a patent applications review (1994-2017)

Marie Godar (UGent) , Hans de Haard, Christophe Blanchetot and Jacobus Rasser

(2018) EXPERT OPINION ON THERAPEUTIC PATENTS. 28(3). p.251-276
Mark
- journalArticle
- A1
- open access
Personalized medicine with biologics for severe type 2 asthma : current status and future prospects

Marie Godar (UGent) , Christophe Blanchetot, Hans de Haard, Bart Lambrecht (UGent) and Guy Brusselle (UGent)

(2018) MABS . 10(1). p.34-45
Mark
- journalArticle
A bispecific antibody strategy to target multiple type 2 cytokines in asthma

Marie Godar (UGent) , Kim Deswarte (UGent) , Karl Vergote (UGent) , Michael Saunders, Hans de Haard, Hamida Hammad (UGent) , Christophe Blanchetot and Bart Lambrecht (UGent)

(2018) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 142(4). p.1185-1193
Mark
- journalArticle
Structural basis of latent TGF-beta 1 presentation and activation by GARP on human regulatory T cells

Stephanie Lienart, Romain Merceron (UGent) , Christophe Vanderaa, Fanny Lambert, Didier Colau, Julie Stockis, Bas van der Woning, Hans De Haard, Michael Saunders, Pierre G. Coulie, et al.

(2018) SCIENCE. 362(6417). p.952-956
Mark
- journalArticle
- A1
- open access
Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy

Julie Jacobs, Vanessa Deschoolmeester, Christian Rolfo, Karen Zwaenepoel, Jolien Van den Bossche, Christophe Deben, Karen Silence, Hans de Haard, Christophe Hermans, Sylvie Rottey (UGent) , et al.

(2017) ONCOTARGET . 8(43). p.74058-74067
Mark
Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies

Philippe Aftimos, Christian Rolfo, Sylvie Rottey (UGent) , Fritz Offner (UGent) , Dominique Bron, Marie Maerevoet, Jean-Charles Soria, Mahan Moshir, Torsten Dreier, Luc Van Rompaey, et al.

(2017) CLINICAL CANCER RESEARCH. 23(21). p.6411-6420
Mark
- journalArticle
- A1
- open access
Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy

Marie Godar (UGent) , Virginia Morello, Ava Sadi, Anna Hultberg, Natalie De Jonge, Cristina Basilico, Valérie Hanssens, Michael Saunders, Bart Lambrecht (UGent) , Mohamed El Khattabi, et al.

(2016) SCIENTIFIC REPORTS. 6.
Mark
- conference
- C3
Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE antibody ARGX-110

Jean-Marie Michot, Marie Maerevoet, Philippe Georges Aftimos, Sylvie Rottey (UGent) , Christian Diego Rolfo, Fritz Offner (UGent) , Luc Van Rompaey, Mahan Moshir, Hans de Haard, Karen Silence, et al.

(2016) JOURNAL OF CLINICAL ONCOLOGY. 34(15, suppl.).
Mark
Depleting MET-expressing tumor cells by ADCC provides a therapeutic advantage over inhibiting HGF/MET signaling

Anna Hultberg, Virginia Morello, Leander Huyghe, Natalie De Jonge, Christophe Blanchetot, Valérie Hanssens, Gitte de Boeck, Karen Silence, Els Festjens, Raimond Heukers, et al.

(2015) CANCER RESEARCH. 75(16). p.3373-3383
Mark
Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis

Ken Coppieters (UGent) , Torsten Dreier, Karen Silence, Hans de Haard, Marc Lauwereys, Peter Casteels, Els Beirnaert, Heidi Jonckheere, Christophe Van De Wiele (UGent) , Ludovicus Staelens, et al.

(2006) ARTHRITIS AND RHEUMATISM. 54(6). p.1856-1866

Academic Bibliography

Therapeutic bispecific antibody formats : a patent applications review (1994-2017)

Personalized medicine with biologics for severe type 2 asthma : current status and future prospects

A bispecific antibody strategy to target multiple type 2 cytokines in asthma

Structural basis of latent TGF-beta 1 presentation and activation by GARP on human regulatory T cells

Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy

Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies

Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy

Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE antibody ARGX-110

Depleting MET-expressing tumor cells by ADCC provides a therapeutic advantage over inhibiting HGF/MET signaling

Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis

Contents

Support

Contact